{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:15:15Z","timestamp":1792271715705,"version":"4.4.0"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Spero Therapeutics","award":["University of Liverpool"],"award-info":[{"award-number":["University of Liverpool"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>Tebipenem pivoxil HBr (TBPM-PI-HBr) is a novel orally bioavailable carbapenem. The active moiety is tebipenem. Tebipenem pivoxil is licensed for use in Japan in children with ear, nose, and throat infections and respiratory infections. The HBr salt was designed to improve drug substance and drug product properties, including stability. TBPM-PI-HBr is now being developed as an agent for the treatment of complicated urinary tract infections (cUTI) in adults.<\/jats:p>","DOI":"10.1128\/aac.00603-19","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:56:52Z","timestamp":1558583812000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":50,"title":["Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections"],"prefix":"10.1128","volume":"63","author":[{"given":"Laura","family":"McEntee","sequence":"first","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Johnson","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Farrington","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Unsworth","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Dane","sequence":"additional","affiliation":[{"name":"DaneStat Consulting, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Jain","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Cotroneo","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Critchley","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Melnick","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Parr","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-4816","authenticated-orcid":false,"given":"Shampa","family":"Das","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-878X","authenticated-orcid":false,"given":"William","family":"Hope","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"},{"name":"Royal Liverpool Broadgreen University Hospital Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Antibiotic resistance threats report","author":"CDC","year":"2013","unstructured":"CDC. 2013. Antibiotic resistance threats report. CDC, Atlanta, GA."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00752-06"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/11533040-000000000-00000"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/2047-2994-3-9"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00155-06"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp100130b"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2017.01.009"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00188"},{"key":"e_1_3_2_11_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th edition. CLSI document M07\u2013A10. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21010062"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2014.46.4.226"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02307-18"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2008.01.007"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00174"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/344653"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-003-0279-x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01157-17"},{"key":"e_1_3_2_23_2","volume-title":"Abstr ID Week 2017","author":"Lakota EA","year":"2017","unstructured":"Lakota EA, Bader JC, Bhavnani SM, Andes DR, Ambrose PG. 2017. Traditional PK-PD indices for efficacy\u2014can we do better?, poster 831. Abstr ID Week 2017."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmclc.2016.08.001"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.11.008"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03925.x"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.06.015"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.02.001"},{"key":"e_1_3_2_29_2","volume-title":"Clinical microbiology\/virology review","author":"FDA","year":"2018","unstructured":"FDA. 2018. Clinical microbiology\/virology review. Report 4282373. Center for Drug Evaluation and Research, FDA, Silver Spring, MD."},{"key":"e_1_3_2_30_2","volume-title":"Vabomere assessment report","author":"EMA","year":"2018","unstructured":"EMA. 2018. Vabomere assessment report. Report EMA\/CHMP\/700663\/2018. EMA, London, United Kingdom."},{"key":"e_1_3_2_31_2","volume-title":"Zavicefta assessment report","author":"EMA","year":"2016","unstructured":"EMA. 2016. Zavicefta assessment report. Report EMA\/CHMP\/377887\/2016. EMA, London, United Kingdom."},{"key":"e_1_3_2_32_2","volume-title":"CHMP assessment report: Zerbaxa","author":"EMA","year":"2015","unstructured":"EMA. 2015. CHMP assessment report: Zerbaxa. Report EMA\/CHMP\/388494\/2015. EMA, London, United Kingdom."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.suppl_C.29"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00603-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00603-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:29:28Z","timestamp":1645460968000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00603-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1128\/AAC.00603-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.00603-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"2019-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00603-19"}}